Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited
Key Takeaways
- CagriSema is a once-weekly injection that pairs semaglutide (GLP-1) with cagrilintide (a long-acting amylin analog) in a single device
- The phase 3 REDEFINE-1 trial (n=3,417, 68 weeks) reported approximately 22.7% mean body-weight loss in participants without diabetes
- Novo Nordisk filed for U.S. FDA approval during 2025; a brand name has not been announced as of May 2026
- It is investigational. There is no FDA-approved product called CagriSema, no compounded version that mirrors the clinical formulation, and no legitimate consumer route to obtain it
- FormBlends does not sell or supply CagriSema or cagrilintide
Direct answer
CagriSema is an investigational obesity medication from Novo Nordisk that combines semaglutide and cagrilintide in one weekly injection. Semaglutide activates the GLP-1 receptor; cagrilintide activates amylin receptors. Used together, they produced about 22.7% mean weight loss at 68 weeks in the phase 3 REDEFINE-1 trial. As of May 2026, CagriSema is not FDA-approved. Novo filed its U.S. application during 2025 and a launch is possible in 2026 pending review.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The naming: where the word "CagriSema" comes from
- The two ingredients and what they each do
- The REDEFINE program: trials and what they measured
- REDEFINE-1 results in plain numbers
- Side-effect profile from the trial data
- How CagriSema compares to semaglutide alone
- How CagriSema compares to tirzepatide
- Regulatory status and likely timeline
- What "buy CagriSema online" actually gets you
- Who might be a candidate if it launches
- The contrary view: is the trial benefit overstated?
- FAQ
- Sources
The naming: where the word "CagriSema" comes from
The name is a portmanteau. "Cagri" comes from cagrilintide, the amylin analog. "Sema" comes from semaglutide, the GLP-1 agonist most people know as the active ingredient in Wegovy and Ozempic. Novo Nordisk has used "CagriSema" as the development code, not a confirmed brand name. The product may launch under a different commercial name if approved.
The internal Novo development code is also seen as "NN9838" in some pipeline disclosures and "semaglutide 2.4 mg + cagrilintide 2.4 mg" in trial protocols. The 2.4 mg figure refers to the dose of each component delivered in a single weekly injection.
The two ingredients and what they each do
Semaglutide. A synthetic version of the natural hormone GLP-1, modified for once-weekly dosing. It binds GLP-1 receptors in the pancreas (boosting insulin, lowering glucagon in response to meals), the stomach (slowing emptying), and the hypothalamus (signaling satiety). Approved for type 2 diabetes as Ozempic since 2017 and for chronic weight management as Wegovy since 2021.
Cagrilintide. A long-acting analog of amylin. Amylin is co-secreted with insulin from pancreatic beta cells in response to meals. It binds amylin receptors in the area postrema, a region of the brainstem that processes nausea, satiety, and gastric signaling. Amylin agonism slows gastric emptying (an effect that partially overlaps with GLP-1), reduces glucagon, and produces satiety through a separate neural pathway. Cagrilintide alone showed about 10.8% weight loss at 26 weeks in phase 2 testing (Lau et al., Lancet 2021).
The hypothesis behind combining them: GLP-1 and amylin act on partially overlapping circuits, but the amylin signaling pathway adds a satiety signal that GLP-1 alone does not fully recruit. The combined effect was expected to be larger than either drug alone, with somewhat better tolerability than escalating semaglutide to higher doses.
That hypothesis appears to be supported by the REDEFINE data.
The REDEFINE program: trials and what they measured
REDEFINE is the phase 3 program supporting Novo's regulatory filing. The trials reported to date:
| Trial | Population | n | Duration | Primary endpoint |
|---|---|---|---|---|
| REDEFINE-1 | Adults with overweight or obesity (BMI 27+ with comorbidity or 30+), no type 2 diabetes | 3,417 | 68 weeks | Mean % change in body weight |
| REDEFINE-2 | Adults with overweight or obesity and type 2 diabetes | ~1,200 | 68 weeks | Body weight and HbA1c change |
| REDEFINE-3 | Cardiovascular outcomes trial | Larger, ongoing | Variable | MACE composite |
REDEFINE-1 was the primary efficacy trial supporting the obesity indication and was presented at ObesityWeek 2024 with results published shortly after. REDEFINE-2 read out separately and added the diabetes population. REDEFINE-3 is the longer-term cardiovascular outcomes study, modeled on the SELECT trial design that has driven the cardiovascular labeling for semaglutide.
REDEFINE-1 results in plain numbers
The trial randomized participants to one of four arms: CagriSema (semaglutide 2.4 mg + cagrilintide 2.4 mg), semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo. All groups received lifestyle counseling.
| Arm | Mean weight change at 68 weeks | Approximate magnitude |
|---|---|---|
| CagriSema | ~ -22.7% | Largest reported in a phase 3 Novo obesity trial |
| Semaglutide 2.4 mg | ~ -16.1% | Slightly above the 14.9% from STEP 1 |
| Cagrilintide 2.4 mg | ~ -11.8% | Consistent with phase 2 cagrilintide data |
| Placebo | ~ -2.3% | Standard lifestyle-only response |
The combination produced a larger effect than either component alone, by a margin that would translate roughly to an additional 14 to 16 pounds of weight loss for a person starting at 200 pounds compared to semaglutide monotherapy.
Some media coverage characterized the topline number as "less than expected" because earlier analyst models had projected 25%+ weight loss for CagriSema based on phase 2 work. The 22.7% figure was at the lower bound of those projections. Whether 22.7% is "disappointing" is a question of expectations, not biology. By any historical standard for obesity pharmacotherapy, it is a substantial result.
Side-effect profile from the trial data
Gastrointestinal events dominated the adverse-event reports. Nausea, vomiting, diarrhea, and constipation were the most frequently reported issues. Most were mild to moderate and concentrated in the dose-escalation phase (weeks 0-16).
Notable adverse-event observations from REDEFINE-1:
- Discontinuation due to GI adverse events: approximately 6% in the CagriSema arm
- Severe hypoglycemia: rare in the non-diabetes population
- Injection-site reactions: similar to semaglutide
- Heart rate increase: a small mean increase, consistent with prior GLP-1 data
- Gallbladder events: occasional cholelithiasis, consistent with rapid weight-loss patterns observed across GLP-1 trials
The cagrilintide component does carry a class-related boxed-warning consideration for thyroid C-cell tumors (rodent data with related compounds), inherited from the GLP-1 class. Final labeling is pending FDA action.
How CagriSema compares to semaglutide alone
The interpretive question for most patients: is the added cagrilintide component worth the extra complexity?
Reasons to favor semaglutide alone:
- Already FDA-approved; established safety record across millions of patient-years
- Insurance coverage and cost predictability are better established
- The titration protocol is familiar to prescribers
Reasons CagriSema might be preferred if it launches:
- Roughly 6-7 percentage points more mean weight loss based on REDEFINE-1 vs STEP 1 cross-trial
- Potentially a slightly different tolerability profile because of the dual mechanism
- Helpful for patients who plateau on semaglutide alone
Important caveat: cross-trial efficacy comparisons exaggerate or understate differences depending on the trial populations, definitions, and rescue rules. The REDEFINE-1 internal comparison (CagriSema vs sema in the same study) is the more credible source for the size of the combination advantage.
How CagriSema compares to tirzepatide
CagriSema and tirzepatide land in similar territory on weight loss, with different mechanisms.
| Feature | CagriSema | Tirzepatide (Zepbound) |
|---|---|---|
| Mechanism | GLP-1 + amylin (two molecules) | GLP-1 + GIP (one molecule, dual agonist) |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Dosing | Once-weekly subcutaneous | Once-weekly subcutaneous |
| Pivotal weight-loss number | ~22.7% at 68 weeks (REDEFINE-1) | ~22.5% at 72 weeks, 15 mg (SURMOUNT-1) |
| FDA status (May 2026) | Under review | Approved for obesity (Nov 2023) and diabetes (May 2022) |
| Cardiovascular outcomes data | REDEFINE-3 pending | SURPASS-CVOT pending |
No head-to-head trial directly compares CagriSema to tirzepatide. Cross-trial inference suggests the two are roughly equivalent on mean weight loss. The choice in clinical practice would likely depend on tolerability, insurance, and prescriber preference rather than a clear efficacy gap.
Regulatory status and likely timeline
Novo Nordisk has publicly described the U.S. regulatory submission as completed during 2025. Standard FDA review of an obesity drug application typically runs 10 to 12 months. A priority-review pathway could shorten that window, but Novo has not announced priority review.
Possible timeline (subject to change):
- FDA acceptance of filing: 2025
- Action date (PDUFA goal date): late 2026 most likely
- Commercial launch: late 2026 to early 2027 if approved
- EMA and other regulatory submissions: parallel timelines, country-specific
FDA review can also include Advisory Committee meetings if the agency requests one. Whether CagriSema will require an AdComm is not publicly confirmed.
What "buy CagriSema online" actually gets you
Search demand for "buy cagrisema" has risen alongside coverage of REDEFINE-1. The product behind those listings is not the clinical formulation.
What is generally available online under "CagriSema" or "sema + cagri" labeling:
- Powdered "research peptides" labeled as semaglutide or cagrilintide, marketed "for research use only"
- Combined kits requiring user reconstitution and dosing
- Variable, often unverified purity
- No clinical packaging, no NDA-approved labeling, no FDA-registered manufacturing oversight
The legitimate product is a single fixed-ratio pen manufactured by Novo Nordisk under FDA-inspected conditions. That product does not exist on the consumer market. Anything sold as "CagriSema" outside of a clinical trial is not the clinical drug.
This medication is investigational and not FDA-approved. FormBlends does not sell or supply CagriSema, cagrilintide, or any unapproved fixed-ratio combination.
Who might be a candidate if it launches
If CagriSema reaches the U.S. market, the FDA label will define the indicated population. Based on REDEFINE-1 enrollment criteria, the eligible group is likely to mirror Wegovy's: adults with BMI 30+, or BMI 27+ with one or more weight-related comorbidities. REDEFINE-2 may support a separate label for type 2 diabetes.
Likely strong-fit patient profiles:
- Patients who plateaued on Wegovy or Ozempic and want a different ceiling
- Patients with diabetes who want both glycemic and weight benefit
- Patients who tolerated semaglutide reasonably well and prefer to stay in the Novo product family
Likely poor-fit patient profiles:
- Patients who could not tolerate semaglutide because of GI effects (adding amylin tends to add more GI signaling, not less)
- Patients with a history of medullary thyroid carcinoma or MEN-2 (class contraindication, expected to carry over)
- Patients seeking a once-monthly or oral option
The contrary view: is the trial benefit overstated?
A few honest pushbacks to the enthusiasm:
Pushback 1: The 22.7% number is the on-treatment estimand. Different statistical analyses (treatment policy estimand, intent-to-treat with rescue) produce smaller numbers. Real-world adherence is generally worse than trial adherence, which compresses results.
Pushback 2: The semaglutide comparator outperformed STEP 1. Semaglutide in REDEFINE-1 produced ~16% weight loss vs ~14.9% in STEP 1. Either the REDEFINE-1 population was a stronger responder cohort, or the trial protocol was more intensive. Either way, cross-trial comparisons to other drugs (Wegovy 14.9%, tirzepatide 22.5%) should be made cautiously.
Pushback 3: The CagriSema vs sema gap is real but narrower than expected. Earlier projections from phase 2 data suggested a 9-10 percentage point gap. The actual gap was closer to 6-7. The combination still wins, but by less than the marketing implied.
Pushback 4: Long-term durability is unknown. 68 weeks is short for a chronic medication. REDEFINE-3 and longer extension studies will eventually answer whether benefits persist or attenuate. Until then, multi-year data favor the existing approved drugs.
None of these pushbacks change the underlying conclusion that CagriSema works. They temper expectations about how much it works.
Decision framework: how to think about CagriSema before it launches
If you're already on Wegovy and doing well: there is no clinical reason to chase CagriSema. Maintenance on semaglutide is well-supported.
If you've plateaued on Wegovy: the options worth discussing with a prescriber are tirzepatide (if you haven't tried it), additional behavioral support, or waiting for CagriSema if and when it becomes available.
If you're considering starting a GLP-1 right now: starting Wegovy or Zepbound today does not preclude switching to CagriSema later. The "wait for the next drug" strategy means months or years of foregone weight loss for an incremental benefit that may not materialize on the announced timeline.
If you're researching for academic curiosity: the REDEFINE-1 publication is the source document. Press summaries and analyst notes can lag the actual data.
FAQ
What is CagriSema in simple terms? A weekly injection that mixes two obesity drugs (semaglutide and cagrilintide) into one pen, made by Novo Nordisk. In its main phase 3 trial it produced about 22.7% body-weight loss over 68 weeks. It is not yet FDA-approved.
Is CagriSema the same drug as Wegovy? No. Wegovy is semaglutide alone. CagriSema adds a second hormone analog called cagrilintide.
Is cagrilintide a GLP-1? No. Cagrilintide is an analog of amylin, a different hormone from a different cell pathway. The combination uses two distinct signaling systems.
When will CagriSema be available in the U.S.? Novo filed its FDA application during 2025. A possible launch window is late 2026 if review proceeds on a standard schedule. Timelines can shift.
Can I get CagriSema through a compounding pharmacy? No. Compounded "CagriSema" does not legitimately exist. The components, semaglutide and cagrilintide, are not FDA-approved as a combination, and 503A compounders do not have a regulatory pathway to mirror an investigational fixed-ratio biologic.
How does CagriSema compare to retatrutide? Different mechanism and different stage. Retatrutide is a single-molecule triple agonist (GLP-1/GIP/glucagon) from Eli Lilly. CagriSema is a two-molecule combination (GLP-1 + amylin) from Novo Nordisk. Retatrutide's phase 2 produced ~24% weight loss at 48 weeks; CagriSema phase 3 produced ~22.7% at 68 weeks. Phase 3 evidence is stronger than phase 2 evidence.
Will CagriSema cause Ozempic face? Any significant weight loss reduces facial fat pad volume. CagriSema produces a magnitude of loss that would be expected to produce noticeable facial volume change in many users, similar to tirzepatide.
Does CagriSema treat diabetes? REDEFINE-2 tested it in type 2 diabetes and reported both weight and HbA1c effects. A diabetes indication is possible, separate from the obesity filing.
Is CagriSema safer than Wegovy? Not clearly. The combination produced more weight loss and a generally similar adverse-event profile, but with somewhat higher rates of GI discontinuation. "Safer" is not the right framing yet; better-tolerated is also not clearly established.
Why are people calling it CagriSema and not its brand name? Novo has not announced a commercial brand name. The development code became the de facto term in the literature and press.
Can I take semaglutide and cagrilintide separately? Cagrilintide is not commercially available as a standalone product. The component cannot be obtained through legitimate channels outside of a clinical trial.
What's the price likely to be? Unknown. Novo has not announced pricing. Comparable obesity biologics in the U.S. list price around $1,000 to $1,400 per month before insurance and rebates.
Sources
- Garvey WT et al. CagriSema in Adults with Overweight or Obesity Without Type 2 Diabetes: The REDEFINE-1 Trial. Presented at ObesityWeek 2024.
- Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
- Novo Nordisk. REDEFINE Trial Program Disclosure Documents. 2024-2025.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023.
- Hall KD. Energy compensation and metabolic adaptation: 'The Biggest Loser' study reinterpreted. Obesity. 2022.
- FDA. Guidance for Industry: Developing Products for Weight Management. 2007 (latest revision).
- American Diabetes Association. Standards of Care in Diabetes - 2025. Diabetes Care. 2025.
- Endocrine Society. Pharmacological Management of Obesity Clinical Practice Guideline. 2024 update.
- Knop FK et al. Oral semaglutide and the gut: effects on appetite and weight loss. Cell Metabolism. 2023.
- Novo Nordisk Annual Report 2024. Pipeline disclosures.
- The Obesity Society. Position Statement on Pharmacotherapy for Obesity. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a telehealth platform that connects patients with independent licensed clinicians and U.S.-based pharmacies. We do not manufacture, prescribe, dispense, or supply CagriSema, cagrilintide, or any investigational obesity medication. Clinical decisions belong to your prescribing clinician.
Investigational Drug Notice. CagriSema and cagrilintide are investigational. They are not FDA-approved as of May 2026 and not commercially available in the United States. Products sold online as "CagriSema" or research-grade cagrilintide are not the clinical formulation and have not been evaluated by the FDA for safety, purity, or efficacy.
Results Disclaimer. Trial outcomes referenced here, including the ~22.7% mean weight loss in REDEFINE-1, reflect group averages in a controlled clinical setting. Individual outcomes vary with adherence, baseline characteristics, diet, exercise, and other treatments. Real-world results commonly fall short of trial averages.
Trademark Notice. CagriSema is a development name used by Novo Nordisk A/S; the final commercial name, if approved, may differ. Wegovy and Ozempic are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.